Edition:
India

Egalet Corp (EGLT.OQ)

EGLT.OQ on NASDAQ Stock Exchange Global Market

0.96USD
19 Jan 2018
Change (% chg)

$0.05 (+5.93%)
Prev Close
$0.91
Open
$0.89
Day's High
$0.97
Day's Low
$0.89
Volume
104,764
Avg. Vol
245,239
52-wk High
$5.58
52-wk Low
$0.80

Chart for

About

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using... (more)

Overall

Beta: 0.29
Market Cap(Mil.): $53.81
Shares Outstanding(Mil.): 43.05
Dividend: --
Yield (%): --

Financials

BRIEF-Broadfin Capital Reports 9.99 Pct Passive Stake In Egalet Corp

* BROADFIN CAPITAL LLC REPORTS A 9.99 PCT PASSIVE STAKE IN EGALET CORP AS OF DEC 27, 2017 - SEC FILING Source text: (http://bit.ly/2lRMZcH) Further company coverage:

04 Jan 2018

BRIEF-Egalet Partners With Orapharma To Co-Promote Sprix Nasal Spray

* EGALET PARTNERS WITH ORAPHARMA TO CO-PROMOTE SPRIX® NASAL SPRAY

03 Jan 2018

BRIEF-Egalet Reduces Announces Refinancing Of Existing Convertible Notes

* EGALET REDUCES DEBT OBLIGATION, EXTENDS MATURITY AND LOWERS ANNUAL INTEREST PAYMENTS THROUGH REFINANCING OF EXISTING CONVERTIBLE NOTES

20 Dec 2017

BRIEF-Egalet Receives FDA Tentative Approval For Chronic Pain Treatment Drug

* EGALET RECEIVES FDA TENTATIVE APPROVAL FOR EXPANDED LABEL FOR ARYMO® ER (MORPHINE SULFATE) C-II, AN EXTENDED-RELEASE MORPHINE PRODUCT FORMULATED WITH ABUSE-DETERRENT PROPERTIES FOR TREATMENT OF CHRONIC PAIN

15 Dec 2017

BRIEF-Egalet Says Notified Verbally By CVS Caremark That Sprix Will No Longer Be On Formulary For A Portion Of Commercial Covered Lives Beginning 2018

* EGALET - NOTIFIED VERBALLY BY CVS CAREMARK THAT SPRIX WILL NO LONGER BE ON FORMULARY FOR A PORTION OF COMMERCIAL COVERED LIVES BEGINNING JAN 1, 2018

07 Dec 2017

BRIEF-Egalet Corp's Phase 3 Study Of Egalet-002 In Patients With Moderate-To-Severe Chronic Low Back Pain Meets Primary Endpoint​

* EGALET ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING EFFICACY AND SAFETY OF EGALET-002 IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN

28 Nov 2017

BRIEF-Egalet Corp Says ‍Apotex Has Lost Right To Launch An Authorized Generic Version Of Sprix Nasal Spray​

* EGALET CORP - ‍COMPANY DID NOT RECEIVE ANY WRITTEN NOTIFICATION ON OR BEFORE NOTIFICATION DEADLINE FOR PRODUCT LAUNCH FROM APOTEX CORP & APOTEX INC​

28 Nov 2017

BRIEF-EGALET ANNOUNCES LATE-STAGE STUDY DATA ON EGALET-002

* EGALET ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 SAFETY STUDY EVALUATING SAFETY OF EGALET-002

17 Nov 2017

BRIEF-Egalet announces ARYMO ER added to large payer Medicare Part D Formulary

* A large payer will provide coverage of ARYMO ER extended-release tablets for oral use -CII for its Medicare Part D Members​

06 Nov 2017

Earnings vs. Estimates